cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-19 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
After the Second World War, researchers began conducting large-scale surveys and proposing broad social indicators to track well-being within nations and in cross-national comparisons. Based on their results, Richard Easterlin (1926–2024) formulated the Easterlin paradox—the observation that richer individuals in a nation report higher happiness than poorer ones, although the average happiness of the population does not increase as the nation's average income rises. Various models of well-being were proposed in the second half of the 20th century and the beginning of the 21st century, including Ed Diener's (1946–2021) tripartite model of subjective well-being, Carol Ryff's (born 1950) six-factor model of psychological well-being, and Martin Seligman's (born 1942) PERMA model. Derek Parfit (1942–2017) analyzed traditional theories of well-being and introduced the influential distinction between hedonism, desire theories, and objective list theories. Another key development was the emergence of positive psychology in the late 1990s, focusing on human flourishing and optimal functioning in contrast to the traditional emphasis of psychological research on illness and dysfunction. The 20th and 21st centuries also saw growing interest in the relation between well-being, economy, and public policy, as governments and international organizations began integrating research on well-being into political decision-making.
In June 2012, Riff Raff released the .Summer of Surf mixtape. He signed with Diplo's label Mad Decent in June 2012. The same year he released the album, The Golden Alien, independently in July which feature tracks produced by MikeChekMusic, "Freeze Dried", "Obtuse Angle". It was followed by the release of the mixtape, Birth of an Icon, in August, which was listed by Stereogum as their "Mixtape of the Week".
=== Sublima === In 2019, Cave founded Sublima Pharmaceuticals in an effort to develop the first non-hormonal birth control in the United States. She made this decision after having some side effects from her previous birth control pill. After three to four doctors and a span of six months, they figured out that the hormonal birth control was the problem. Sublima is still in early stages. Cave is expecting the fundraise after the drug gets approved by the FDA. The drug is currently in Phase Three of clinical trials.
Sources: en.wikipedia.org
=== Development after independence === Madras State, the precursor to the present-day state of Tamil Nadu, was created after India became a republic on 26 January 1950. It consisted of present-day Tamil Nadu and parts of present-day Andhra Pradesh, Karnataka, and Kerala. The first legislature of the Madras State to be elected on the basis of universal suffrage was constituted on 1 March 1952, after the general elections held in January 1952. The state was split up along linguistic lines in 1953, carving out Andhra State. Under the States Reorganisation Act, 1956, the states of Kerala and Mysore State were carved out of Madras State. Under the Andhra Pradesh and Madras Alteration of Boundaries Act, 1959, with effect from 1 April 1960, Tiruttani taluk and Pallipattu sub-taluk of Chittoor district of Andhra Pradesh were transferred to Madras in exchange for territories from the Chingelput and Salem districts.
Analogous to the behavior of other chalcogens, selenium forms hydrogen selenide, H2Se. It is a strongly odiferous, toxic, and colorless gas. It is more acidic than H2S. In solution it ionizes to HSe−. The selenide dianion Se2− forms a variety of compounds, including the minerals from which selenium is obtained commercially. Illustrative selenides include mercury selenide (HgSe), lead selenide (PbSe), zinc selenide (ZnSe), and copper indium gallium diselenide (Cu(Ga,In)Se2). These materials are semiconductors. With highly electropositive metals, such as aluminium, these selenides are prone to hydrolysis, which may be described by this idealized equation:
== Synthesis, basic properties, and structure == The carbon atom in cyanogen bromide is bonded to bromine by a single bond and to nitrogen by a triple bond (i.e. Br−C≡N). The compound is linear and polar, but it does not spontaneously ionize in water. It dissolves in both water and polar organic solvents. Cyanogen bromide can be prepared by oxidation of sodium cyanide with bromine, which proceeds in two steps via the intermediate cyanogen ((CN)2):
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.